Assembly Biosciences CEO Dr. John McHutchison Named Recipient of the Prestigious Advance 2020 Global Impact Award
October 15 2020 - 8:00AM
Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage
biotechnology company developing innovative therapeutics targeting
hepatitis B virus (HBV) and diseases associated with the
microbiome, today announced that John McHutchison AO, MD – the
company’s CEO and president– was named the recipient of the Advance
2020 Global Impact award. The Advance awards recognize the work of
remarkable global Australians making an extraordinary
impact worldwide.
The award honors Dr. McHutchison’s innovative work in developing
life-changing and curative therapies for patients with hepatitis C
virus (HCV). These treatments are in part a result of his 30-year
personal investment researching and developing therapeutics for
this previously incurable disease. Now at the helm of Assembly
Biosciences, Dr. McHutchison is dedicated to pioneering a new class
of therapeutics for HBV, which impacts approximately 250 million
people globally.
“It is a great honor to be named a winner of this highly
prestigious award,” said Dr. McHutchison. “There are a quarter of a
billion people worldwide who are chronically infected with HBV and
deserve better outcomes, as have now been delivered for people with
HCV infection. Having my contributions to the HCV field recognized
by the Advance awards commission is truly inspiring and reinforces
my commitment and confidence that we can achieve a future with
curative treatment regimens for patients with HBV infection.”
In its ninth year, the Advance Awards celebrates Australian
global leaders that represent an extraordinary group of talented
innovators who have demonstrated excellence in their respective
fields on the global stage, ranging from technology innovation,
financial services and healthcare, to social impact,
sustainability, and the arts. The Awards are the only of their kind
that recognize the contributions of the one million Australians
living abroad.
The full list of Advance 2020 award recipients is available at
www.advance.org/advance-awards. More information about Assembly
Biosciences is available at www.assemblybio.com.
About Assembly BiosciencesAssembly Biosciences,
Inc. is a clinical-stage biotechnology company developing
innovative therapeutics targeting hepatitis B virus (HBV) and
diseases associated with the microbiome. The HBV program is focused
on advancing a new class of potent, oral core inhibitors that have
the potential to increase cure rates for chronically infected
patients. The microbiome program is developing novel oral live
microbial biotherapeutic candidates with Assembly’s fully
integrated platform, including a robust process for strain
identification and selection, GMP manufacturing expertise and
targeted delivery to the lower gastrointestinal tract with the
GEMICEL® technology For more information, visit
assemblybio.com.
Investor Contact
Assembly Biosciences, Inc.
Lauren Glaser
Senior Vice President, Investor Relations and Corporate Affairs
(415) 521-3828
lglaser@assemblybio.com
Media Contact
Sam Brown Inc.
Audra Friis
(917) 519-9577
ASMBMedia@sambrown.com
Assembly Biosciences (NASDAQ:ASMB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Assembly Biosciences (NASDAQ:ASMB)
Historical Stock Chart
From Sep 2023 to Sep 2024